Maha Hussain, MD, on Prostate Cancer: Results From the PROSPER Trial
2018 Genitourinary Cancers SymposiumMaha Hussain, MD, of Northwestern University, discusses phase III findings on enzalutamide in men with nonmetastatic castration-resistant prostate cancer (Abstract 3).
Related Videos
Gregory R. Pond, PhD, on Urothelial Cancer: Advance in Prognosis
Gregory R. Pond, PhD, of McMaster University, discusses a new six-factor prognostic model for patients with advanced urothelial carcinoma receiving post platinum atezolizumab (Abst...
Robert G. Bristow, MD, PhD, on Prostate Cancer: Keynote Lecture
Robert G. Bristow, MD, PhD, of Manchester Cancer Research Centre, discusses germline and somatic mutations; new ways to generate biomarkers that may describe tumor complexity; and ...
Eric J. Small, MD, on Prostate Cancer: Results From the SPARTAN Trial
Eric J. Small, MD, of the University of California, San Francisco, discusses phase III findings on apalutamide vs placebo in patients with nonmetastatic castration-resistant prosta...
Patrick Schöffski, MD, MPH, on RCC: Final Results of the EORTC 90101 CREATE Trial
Patrick Schöffski, MD, MPH, of Catholic University Leuven, discusses findings on the effect of crizotinib on disease control in patients with advanced papillary renal cell carcinom...
Daniel J. George, MD, on RCC: Results From the Alliance A031203 CABOSUN Trial
Daniel J. George, MD, of Duke University Medical Center, discusses study findings on cabozantinib vs sunitinib for previously untreated patients with advanced renal cell carcinoma ...
